Navigation Links
Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen in a Single Trial

LUTON, UK, Friday 15 June 2007: Analysis of the entire population of a single trial has demonstrated that survival in early breast cancer can be significantly improved by switching from tamoxifen to anastrozole (Arimidex). An analysis of the 'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in The Journal of Clinical Oncology, confirms that postmenopausal women who have been taking tamoxifen as part of their treatment for early breast cancer for two years can significantly reduce the chance of their breast cancer returning by switching therapy to anastrozole.1

The ARNO 95 study, involving 979 patients, was designed to evaluate whether post-menopausal women with hormone-receptor positive early breast cancer who had been receiving endocrine treatment with tamoxifen for two years would benefit from switching to an aromatase inhibitor (AI). The study demonstrated that women switching to anastrozole (n=489) rather than remaining on tamoxifen (n= 490) experienced1: · 34% reduction in the relative risk of recurrence (HR = 0.66; p=0.049) · 47% improvement in overall survival (HR = 0.53; p=0.045) · Fewer serious adverse events (22.7% v 30.8%) (OR = 0.66; p=0.0065)

"This new study is the first individual aromatase inhibitor trial showing a benefit in overall survival in the whole of the study population. The result is particularly striking in that this was a substantial group of patients with a relatively good prognosis (74% node negative). The reason that this result is so important is that improvement in overall survival is the biggest prize of all," said Professor Jeffrey Tobias, Consultant Oncologist and Professor of Cancer medicine, University College London. "These data confirm that women who have not had the advantage of starting their adjuvant therapy with an aromatase inhibitor and are cu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
2. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
3. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
4. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
5. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
6. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
7. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
10. Once Daily, Extended-Release Ropinirole Improves Parkinsons Symptoms in Patients not Optimally Controlled With Levodopa
11. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Post Your Comments:
(Date:5/8/2008)...Network Completes 13 Phase-I Clinical Trials; Re...opment, EL SEGUNDO, Calif., May 8 /-...linical trial research service business specializi...evelopment for FDA approval,reports it completed ... 34,active trials in late stage drug development-a...
(Date:5/8/2008)...improvement in ADHD symptoms in adults, WASHINGTO... SHP,Nasdaq: SHPGY), the global specialty biophar... a phase III pivotal study in which VYVANSE,demons...it Hyperactivity,Disorder (ADHD) symptoms in adult...ults with ADHD often find it challenging to focus ...
(Date:5/8/2008)...to Produce Therapeutic Proteins at Tumor,Site, ...ire/ -- Using gene,therapy, plastic surgeons have ...aps placed on cancerous tumors on rats with a 79 p...tudy in the May issue of Plastic and,Reconstructiv...American,Society of Plastic Surgeons (ASPS). This ...
(Date:5/8/2008)... Center Investigators to Assess BSI-201 ..., BRISBANE, Calif., May 8 /- BiPar S...se 2 clinical trial programs for its lead,product,...or clinical trial,of BSI-201 that BiPar has launch...als in breast and brain cancer., The company is e...
Breaking Medicine Technology:DaVita Clinical Research Completes Record Number of Renal Trials in 2007 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Britney and K Fed doing it all wrong MU family researcher says 6222 1Britney and K Fed doing it all wrong MU family researcher says 6222 2Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 6220 1Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 6220 2Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 1Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 2Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 3Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 4Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 5Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic Making Influenza Vaccination Convenient for Shoppers 6216 6Hormonal Changes and Depression 3A What is the Connection 3F 6212 1Hormonal Changes and Depression 3A What is the Connection 3F 6212 2Hormonal Changes and Depression 3A What is the Connection 3F 6212 3Hormonal Changes and Depression 3A What is the Connection 3F 6212 4
...ESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals... preclinical,studies of INNO-406, a potent oral du...sistant or treatment-intolerant chronic,myelogenou...ciation,for Cancer Research Annual Meeting. The me...eles Convention Center in Los Angeles,California....
...inical Data Presented on Valopicitabine Combined,w...NA, Spain, April 12, 2007 /PRNewswire-FirstCall/ -...ults from two phase,IIb studies of the novel combi...erferon alfa-2a (Pegasys(R)) in both treatment-nai...th the genotype-1,strain of the hepatitis C virus ...
Other Medicine Technology:Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7
(Date:5/12/2008)...roject proceeds despite non-compliance with Califo...y Act (CEQA)., LOS ANGELES, May 12 /PRNewswire-US...(PHCMC) today went ahead with the planned expansio...r Court Judge Thomas I. McKnew,Jr. has upheld cha...lawed.,The groundbreaking ceremony held today appe...
(Date:5/12/2008)... First approved dental anesthetic reversa...r Pharmaceuticals, Inc., a,dental specialty pharma...States Food and Drug Administration (FDA) has gran...ine mesylate). OraVerse is the first,pharmaceutica...anesthesia,and the associated functional deficits ...
(Date:5/12/2008)...GAITHERSBURG, Md., May 12 /PRNewswire-FirstCall/ -...at it will host a conference call and live,webcast...ercell AG (VSE:,ICLL) and Iomai have entered into ... will acquire Iomai for USD 6.60 per share represe...y USD 189 million (EUR 122 million)., The confere...
(Date:5/12/2008)...PHOENIX, May 12 /PRNewswire-FirstCall/ -- NutraCea...bilized rice bran (SRB), nutrient research and,tec... first quarter ended,March 31, 2008. Consolidated ...st quarter of 2008, compared to consolidated net r...007. The $3.1 million increase was,primarily due t...
Breaking Medicine News(10 mins):Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Novalar Receives FDA Approval for OraVerse(TM) 2Health News:Novalar Receives FDA Approval for OraVerse(TM) 3Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 2Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 3Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6
... had approved the drug for use to treat the cancer...spokeswoman for the Department of Health and Agein... Scheme.// "The next step with any drug is to go t...spokesperson. The history of the drug use reveals ...
...igin has died in Singapore a few days after the op...quiry. The donor is reported to have suffered from...agles Hospital, // according to the transplant sur...ear-old woman who got the liver in November, recov...
...te of Science throws light on cells that could pre...findings appear in the February issue of Nature Ne...obiology Department at Weizmann led the study, //w... delaying the onset of cognitive deterioration in ...
...entist who was jailed for one year in 2005, has no...practicisig. Azari allowed her boyfriend Omid Amid...er patients with devastating consequences. Mazahe... using an anesthetic and placed fillings that bare...
Other Medicine News:Health News:Weizmann Institute of Science says Immune Cells Could Help Maintain Brain Function 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: